SCHEMBL404722

SCHEMBL404722

CCOC(=O)Nc1c(F)cc(C)cc1C#N

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NLRP3 Q96P20 4/20 0.46
CYP1A2 P05177 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
SMN1; SMN2 Q16637 3/20 0.42
ALDH1A1 P00352 2/20 0.40
GAA P10253 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
KDM4E B2RXH2 3/20 0.39
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
GLA P06280 1/20 0.39
POLB P06746 1/20 0.39
EGFR P00533 1/20 0.39
LMNA P02545 1/20 0.37
KCNQ3 O43525 1/20 0.37
KCNQ2 O43526 1/20 0.37
KCNQ4 P56696 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9021094 0.85 NLRP3 (0.41) NLRP3CYP1A2CYP2C9CYP2C19SMN1; SMN2
SCHEMBL462898 0.84 KCNQ2 (0.46) NLRP3CYP1A2CYP2C9CYP2C19ALDH1A1
SCHEMBL9021409 0.82 NLRP3 (0.39) NLRP3CYP1A2CYP2C9CYP2C19SMN1; SMN2
SCHEMBL11500164 0.81 NLRP3 (0.44) NLRP3CYP1A2CYP2C9CYP2C19SMN1; SMN2
SCHEMBL7976076 0.81 NLRP3 (0.60) NLRP3CYP1A2CYP2C19SMN1; SMN2ALDH1A1
SCHEMBL404508 0.77 NLRP3 (0.51) NLRP3CYP1A2CYP2C9CYP2C19SMN1; SMN2
SCHEMBL158695 0.77 LMNA (0.40) CYP2C9CYP2C19SMN1; SMN2MEN1KMT2A
SCHEMBL2720869 0.77 ADRB2 (0.48) NLRP3SMN1; SMN2ALDH1A1GAAL3MBTL1
Hydrochloric Acid SCHEMBL10882348 0.77 KCNQ3 (0.37) NLRP3CYP1A2CYP2C9CYP2C19SMN1; SMN2
SCHEMBL29798791 0.77 LMNA (0.40) CYP2C9CYP2C19SMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120065187-A1 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE ALCON RESEARCH, LTD (US) 2012-03-15 US disclosed
US-20110257137-A1 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE KALYPSYS, INC. (US) 2011-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120065187-A1 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE HRH4, HRH3, HRH2 NLRP3 666/4885CYP1A2 2609/4885CYP2C9 2484/4885
US-20110257137-A1 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE HRH4, HRH3, HRH2 NLRP3 666/4885CYP1A2 2609/4885CYP2C9 2484/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.